<![CDATA[The growing application of artificial intelligence in assisted reproductive technologies raises significant legal and ethical concerns regarding embryo selection, reproductive data protection, medical responsibility, and patient rights. Rapid technological development has challenged existing legal frameworks because conventional health regulations do not fully address the distinctive risks created by algorithmic decision making in reproductive medicine. This study examines the legal implications of using artificial intelligence in artificial insemination and assesses the capacity of existing regulations to protect patients while accommodating medical innovation. The study applies comparative legal research by examining regulatory approaches in the European Union, the United Kingdom, and Japan. The findings show that existing regulations do not provide comprehensive standards for algorithmic transparency, system validation, genetic and reproductive data protection, human supervision, and medical liability when artificial intelligence contributes to clinical decisions or patient harm. The comparison also identifies substantial differences in regulatory supervision, approval mechanisms, accountability standards, and patient safeguards across the selected jurisdictions. These regulatory differences create legal uncertainty for healthcare professionals, technology developers, and patients who rely on artificial intelligence in reproductive treatment.]]>
